Sorrento Therapeutics, Inc. Stock price
Is Sorrento Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Sorrento Therapeutics, Inc. Stock Analysis
Analyst Opinions
7 Analysts have issued a Sorrento Therapeutics, Inc. forecast:
Analyst Opinions
7 Analysts have issued a Sorrento Therapeutics, Inc. forecast:
Don't miss a Thing! We will send you all news about Sorrento Therapeutics, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Dr. Ji |
| Founded | 1989 |
| Website | sorrentotherapeutics.com |


